sellWeak cluster of 310b5-1 plan
Matthew K Fust sold $716k of CRNX
director at Crinetics Pharmaceuticals, Inc.. 16,000 shares at an average of $44.75, traded Sep 26, 2025, filed Sep 30, 2025.
Warning score
26Value
$716k
16,000 shares
Holdings after
22,836
-41% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +21Trade size$716k at market
- +10Share of holdings soldSold 41% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001658247-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 26, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $1.91 | $19k | 38,836 | Sep 30, 2025 |
| Sep 26, 2025 | SOpen-market sale Common Stock10b5-1 | -16,000 | $44.75 | $716k | 22,836 | Sep 30, 2025 |
| Sep 26, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 2,092 | Sep 30, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $225k 5,000 shares | -7% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $213k 5,000 shares | -7% | |
| 7Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $209k 5,000 shares | -7% | |
| 32Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $180k 4,000 shares | -4% | |
| 0Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $161k 5,000 shares | -5% | |
| 14Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $913k 30,000 shares | -31% | |
| 7Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $189k 6,492 shares | -9% | |
| 15Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $3.1M 97,483 shares | -49% | |
| 22Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $197k 5,770 shares | -5% | |
| 39Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $593k 17,338 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.